These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10644081)

  • 1. Antagonistic interaction between the convulsant activities of pefloxacin and its main metabolite norfloxacin in rats.
    Delon A; Levasseur LM; Giraudon M; Bouquet S; Couet W
    Pharm Res; 1999 Dec; 16(12):1894-7. PubMed ID: 10644081
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of pefloxacin and norfloxacin in rats.
    Delon A; Huguet F; Courtois P; Vierfond JM; Bouquet S; Couet W
    J Pharmacol Exp Ther; 1997 Feb; 280(2):983-7. PubMed ID: 9023315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extension of the isobolographic approach to interactions studies between more than two drugs: illustration with the convulsant interaction between pefloxacin, norfloxacin, and theophylline in rats.
    Brochot C; Marchand S; Couet W; Gelman A; Bois FY
    J Pharm Sci; 2004 Mar; 93(3):553-62. PubMed ID: 14762894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach for early assessment of the epileptogenic potential of quinolones.
    Delon A; Pariat C; Courtois P; Bouquet S; Couet W
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2756-8. PubMed ID: 9756792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between pefloxacin and theophylline in rats.
    Levasseur LM; Delon A; Greco WR; Faury P; Bouquet S; Couet W
    Pharm Res; 1998 Jul; 15(7):1069-76. PubMed ID: 9688062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between pefloxacin and aminophylline in genetically epilepsy-prone rats.
    Imperatore C; Trimarchi GR; De Sarro A
    J Pharm Pharmacol; 1997 Oct; 49(10):1025-9. PubMed ID: 9364414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Yersinia pseudotuberculosis sensitivity to fluoroquinolones and the efficacy of pefloxacin in experimental pseudotuberculosis].
    Zaĭtseva EA; Shubin FN; Besednova NN
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (5):49-52. PubMed ID: 9432847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration of pefloxacin and its desmethyl metabolite into the uroepithelium after a 800-mg single oral dose in human patients.
    Moreau JL; Royer-Morrot MJ; Lozniewski A; Trackoen G; Delavault P; Royer RJ
    Eur J Clin Pharmacol; 1996; 49(5):401-5. PubMed ID: 8866637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats.
    Marchand S; Pariat C; Bouquet S; Courtois P; Couet W
    Br J Pharmacol; 2000 Apr; 129(8):1609-16. PubMed ID: 10780965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norfloxacin-induced electroencephalogram alteration and seizures in rats are not triggered by enhanced levels of intracerebral glutamate.
    Chenel M; Limosin A; Marchand S; Paquereau J; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3660-2. PubMed ID: 14576142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of pefloxacin and its metabolite norfloxacin in male and female ducks.
    Dimitrova D; Moutafchieva R; Kanelov I; Dinev T; Yanev S; Pandova B; Lashev L
    J Vet Pharmacol Ther; 2008 Apr; 31(2):167-70. PubMed ID: 18307509
    [No Abstract]   [Full Text] [Related]  

  • 12. Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography.
    Abanmi N; Zaghloul I; El Sayed N; Al-Khamis KI
    Ther Drug Monit; 1996 Apr; 18(2):158-63. PubMed ID: 8721279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats.
    Cadart M; Marchand S; Pariat C; Bouquet S; Couet W
    Pharm Res; 2002 Feb; 19(2):209-14. PubMed ID: 11883649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of pefloxacin-induced pain.
    Kukushkin ML; Igonkina SI; Guskova TA
    Bull Exp Biol Med; 2004 Apr; 137(4):336-8. PubMed ID: 15452594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in brain interleukin-1beta following the coadministration of norfloxacin with biphenylacetic acid in rats.
    Zhang LR; Li XT; Tang WL; Wang YM; Cheng NN; Chen BY
    Eur J Pharmacol; 2006 Aug; 543(1-3):21-6. PubMed ID: 16824509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
    Fukuda H; Kawamura Y
    Jpn J Antibiot; 2002 Jun; 55(3):270-80. PubMed ID: 12199111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens.
    Pant S; Rao GS; Sastry KV; Tripathi HC; Jagmohan ; Malik JK
    Br Poult Sci; 2005 Oct; 46(5):615-20. PubMed ID: 16359117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway?
    Griffiths NM; Hirst BH; Simmons NL
    J Pharmacol Exp Ther; 1994 May; 269(2):496-502. PubMed ID: 8182517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients.
    D'Antonio D; Iacone A; Fioritoni G; Betti S; Dell'Isola M; Quaglietta AM; Accorsi P; Pantalone V; Recchia A; Piergallini A
    Drugs Exp Clin Res; 1992; 18(4):141-6. PubMed ID: 1451644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pefloxacin-induced achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen.
    Simonin MA; Gegout-Pottie P; Minn A; Gillet P; Netter P; Terlain B
    Antimicrob Agents Chemother; 2000 Apr; 44(4):867-72. PubMed ID: 10722483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.